학술논문
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B.
Document Type
Academic Journal
Author
Mateos-Muñoz B; Hospital Universitario Ramón y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, Madrid, Spain.; Buti M; Hepatology Department, Hospital Universitario Valle Hebron Hospital, CIBEREHD, Barcelona, Spain.; Vázquez IF; Gastroenterology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.; Conde MH; Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.; Bernal-Monterde V; Gastroenterology Department, Hospital Miguel Servet, Zaragoza, Spain.; Díaz-Fontenla F; Gastroenterology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.; Morillas RM; Hepatology Unit, Hospital Germans Trias i Pujol, IGTP, CIBEREHD, Badalona, Spain.; García-Buey L; Gastroenterology Department, Hospital Universitario La Princesa Hospital, Madrid, Spain.; Badía E; Gastroenterology Department, Hospital de Burgos, Burgos, Spain.; Miquel M; Gastroenterology Department, Hospital Parc Tauli, CIBEREHD, Sabadell, Spain.; Amador-Navarrete A; Liver Unit, Hospital Universitario Bellvitge, IDIBELL, Barcelona, Spain.; Rodríguez-Tajes S; Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain.; Ramos-Merino L; Infectious Diseases Department, Hospital La Coruña, La Coruña, Spain.; Madejón A; Gastroenterology Department, Hospital Universitario La Paz, IdiPAZ, CIBEREHD, Madrid, Spain.; García-Retortillo M; Gastroenterology Department, Hospital Del Mar, Barcelona, Spain.; Arenas JI; Gastroenterology Department, Hospital de Donostia, Donostia, Spain.; Cabezas J; Gastroenterology Department, IDIVAL-Instituto de Investigación Valdecilla, Hospital Universitario de Valdecilla, Santander, Spain.; Santiago JMG; Gastroenterology Department, Hospital Universitario de Salamanca, Salamanca, Spain.; Fernández-Rodríguez C; Gastroenterology Department, Hospital Universitario Fundación de Alcorcón, Alcorcón, Spain.; Cordero P; Gastroenterology Department, Hospital Universitario Virgen de la Macarena, Seville, Spain.; Diago M; Gastroenterology Department, Hospital General de Valencia, Valencia, Spain.; Mancebo A; Gastroenterology Department, Hospital Universitario de Albacete, Albacete, Spain.; Pardo A; Gastroenterology Department, Hospital Joan XXIII, Tarragona, Spain.; Rodríguez M; Gastroenterology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.; Hoyas E; Gastroenterology Department, Hospital Virgen de Valme, Seville, Spain.; Moreno JJ; Internal Medicine Department, Complejo asistencial de Segovia, Segovia, Spain.; Turnes J; Gastroenterology Department, Hospital de Pontevedra, Pontevedra, Spain.; Simón MÁ; Gastroenterology Department, Hospital Clínico de Zaragoza, Zaragoza, Spain.; Marcos-Fosch C; Hepatology Department, Hospital Universitario Valle Hebron Hospital, CIBEREHD, Barcelona, Spain.; Calleja JL; Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.; Bañares R; Gastroenterology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.; Lens S; Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain.; Garcia-Samaniego J; Gastroenterology Department, Hospital Universitario La Paz, IdiPAZ, CIBEREHD, Madrid, Spain.; Crespo J; Gastroenterology Department, IDIVAL-Instituto de Investigación Valdecilla, Hospital Universitario de Valdecilla, Santander, Spain.; Romero-Gomez M; Gastroenterology Department, Hospital Universitario Virgen del Rocío, CIBEREHD, Seville, Spain.; Gea F; Hospital Universitario Ramón y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, Madrid, Spain.; de Santiago ER; Hospital Universitario Ramón y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, Madrid, Spain.; Moreno S; Hospital Universitario Ramón y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, Madrid, Spain.; Albillos A; Gastroenterology and Hepatology Department, Hospital Universitario Ramon y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, M-607, Km. 9.100, 28034, Madrid, Spain. agustin.albillos@uah.es.
Source
Publisher: Springer Science + Business Media Country of Publication: United States NLM ID: 7902782 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2568 (Electronic) Linking ISSN: 01632116 NLM ISO Abbreviation: Dig Dis Sci Subsets: MEDLINE
Subject
Language
English
Abstract
Background and Aims: HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV).
Methods: Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19.
Results: Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04-0.67, p = 0.01).
Conclusion: Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.
(© 2023. The Author(s).)
Methods: Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19.
Results: Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04-0.67, p = 0.01).
Conclusion: Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.
(© 2023. The Author(s).)